Global Radiopharmaceutical Theragnostic Market By Clinical Trial Phase (Phase I, Phase II, Phase III); By Application (Thyroid cancer, Brain cancer, Lymphoma, Others); By Route of Administration (Oral, Intravenous, Interstitial); By End-Users (Hospitals and Clinics, Pharmaceutical Companies, Research Centers, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Radiopharmaceutical theragnostic procedures are gaining traction in the healthcare sector. Radiopharmaceuticals are medicines which are radioactive in nature, and they can be provided orally, intravenously or interstitially for the treatment of various types of malignancies. A radio pharmacist is responsible for the administration of the medicine. It destroys the cancerous cells by emitting radiations. Radiopharmaceutical theragnostic solutions are becoming increasingly common for cancers that are associated with brain, breast, prostate, bones, lymphoma and thyroid, amongst others. Theranogstics, also known as theranostics, refers to the use a single drug for both diagnostics as well as therapeutics, and nuclear medicine is gaining immensely from this development. Theranostics takes advantage of human anatomy’s biological pathways, as it is highly specific to a particular system, and acquires diagnostic images. These images increases the probability of the drugs targeting specific cells, thereby limiting the impact of radiation on the overall health of the individual. In the future, theragnostic systems is expected to become increasingly common, especially in advanced economies such as the U.S., the UK and Germany, amongst others. Clinical trials are being held by leading companies for the development of highly specific radiopharmaceuticals for theragnostics, which is driving the growth of global radiopharmaceutical theragnostic market.
A major concern associated with the use of radiopharmaceutical theragnostics techniques is the high capital investment that is required for the development of these products, coupled with the regulations pertaining to the clinical trial of these drugs in various countries. The hardware requirement for the development of radiopharmaceutical products are also on the higher side. Furthermore, the emergence of start-ups in this market is restricted to an extend due to the requirement of advanced systems which have the capability of handling algorithms which determine targeted delivery of radiopharmaceutical products. Moreover, highly skilled personnel are also required for managing theranogstics operations, which in turn increases the time to market. Additional scrutiny by government bodies for the development of nuclear medicine also plays a crucial role in increasing the time for the development of these drugs. However, with continuous research and development that is being carried out by major market participants in the global radiopharmaceutical theragnostic market is expected to overcome the limitations and aid for the market growth in the future years.
In terms of revenue, the global radiopharmaceutical theragnostic market was valued at US$ 1123.42 Mn in 2020 and is projected to grow at a CAGR of 15.83% over the forecast period (2021 – 2029). Increasing demand for targeted destruction of cancer cells, along with faster diagnostics of cancer, is expected to drive the growth of the global radiopharmaceutical theragnostic market in the coming years. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Radiopharmaceutical Theragnostic Market Revenue & Forecast, (US$ Million), 2015 – 2029
End Users Outlook:
Based on end users, the global radiopharmaceutical theragnostic market is segmented into hospitals and clinics, pharmaceutical companies, research centers, others. In 2020, hospitals accounted for the major market share in the global radiopharmaceutical theragnostic market. Increasing use of radiopharmaceutical theragnostic for applications such as brain cancer treatment in multi and super speciality hospitals is helping in the growth of revenue of the hospitals segment in the global radiopharmaceutical theragnostic market. However, research centers segment is expected to grow at the fastest rate over the forecast period (2021 – 2029). Companies are also investing heavily in research and development activities as well as collaborating with academic research institutes and hospitals for advanced radiopharmaceuticals theragnostic. For instance, Theragnostics announced a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging. This in turn is expected to fuel the growth of research centers segment in the future years.
Region Outlook:
Based on regions, North America accounted for the lion’s share of revenue in the global radiopharmaceutical theragnostic market in 2020. The presence of a large number of radiopharmaceutical theragnostic providers in the U.S., coupled with the growing number of medical research investments in North America is a major reason for the greater share of North America in the global radiopharmaceutical theragnostic market. However, the Asia Pacific region is expected to show the highest growth during the forecast years in the global radiopharmaceutical theragnostic market, with an estimated CAGR of 17.45% over the forecast period.
Competitive Landscape
The report provides both, qualitative and quantitative research of the global radiopharmaceutical theragnostic market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of key players operating in the global radiopharmaceutical theragnostic market are Advanced Accelerator Applications, A Novartis Company, Chimeric Therapeutics Limited, Fusion Pharma, Lantheus Medical Imaging, Inc., NanoMab, NuView Life Sciences, PentixaPharm GmbH, Precirix, RadioMedix, RayzeBio, Telix Pharmaceuticals Limited, Theragnostics Ltd and Vect-Horus, amongst others.
Global Radiopharmaceutical Theragnostic Market
By Clinical Trial Phase
- Phase I
- Phase II
- Phase III
By Application
- Thyroid cancer
- Brain cancer
- Lymphoma
- Others
By Route of Administration
- Oral
- Intravenous
- Interstitial
By End-Users
- Hospitals and Clinics
- Pharmaceutical Companies
- Research Centers
- Others
By Geography
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Year: 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Radiopharmaceutical Theragnostic Market
6. Market Synopsis:
Radiopharmaceutical Theragnostic Market
7. Radiopharmaceutical Theragnostic Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Radiopharmaceutical Theragnostic Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Radiopharmaceutical Theragnostic Market
8. Global Radiopharmaceutical Theragnostic Market Analysis and
Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
8.2. Global
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phase
8.2.1. Phase I
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2019 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2019 - 2020
8.2.1.5.1.2. Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2019 - 2020
8.2.1.5.2.2. Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2019 - 2020
8.2.1.5.3.2. Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2019 - 2020
8.2.1.5.4.2. Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2019 - 2020
8.2.1.5.5.2. Market
Forecast, 2021 - 2029
8.2.2. Phase II
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2019 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2019 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2019 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2019 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2019 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2019 - 2020
8.2.2.5.5.2. Market
Forecast, 2021 - 2029
8.2.3. Phase
III
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2019 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2019 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2019 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2019 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2019 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2019 - 2020
8.2.3.5.5.2. Market
Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Clinical Trial Phase
9. Global Radiopharmaceutical Theragnostic Market Analysis and
Forecasts, 2021 – 2029
9.1. Overview
9.2. Global
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts, By
Application
9.2.1. Thyroid
cancer
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2019 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2019 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2019 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2019 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2019 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2019 - 2020
9.2.1.5.5.2. Market
Forecast, 2021 - 2029
9.2.2. Brain
cancer
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2019 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2019 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2019 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2019 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2019 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2019 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 - 2029
9.2.3. Lymphoma
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2019 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2019 - 2020
9.2.3.5.1.2. Market
Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2019 - 2020
9.2.3.5.2.2. Market
Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2019 - 2020
9.2.3.5.3.2. Market
Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2019 - 2020
9.2.3.5.4.2. Market
Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2019 - 2020
9.2.3.5.5.2. Market
Forecast, 2021 - 2029
9.2.4. Others
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2019 - 2020
9.2.4.3. Market Forecast, 2021 - 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2019 - 2020
9.2.4.5.1.2. Market
Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2019 - 2020
9.2.4.5.2.2. Market
Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2019 - 2020
9.2.4.5.3.2. Market
Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2019 - 2020
9.2.4.5.4.2. Market
Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2019 - 2020
9.2.4.5.5.2. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Radiopharmaceutical Theragnostic Market Analysis and
Forecasts, 2021 – 2029
10.1. Overview
10.2. Global
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
10.2.1. Oral
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2019 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2019 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2019 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2019 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2019 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2019 - 2020
10.2.1.5.5.2. Market
Forecast, 2021 - 2029
10.2.2. Intravenous
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2019 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2019 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2019 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2019 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2019 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2019 - 2020
10.2.2.5.5.2. Market
Forecast, 2021 - 2029
10.2.3. Interstitial
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2019 - 2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2019 - 2020
10.2.3.5.1.2. Market
Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2019 - 2020
10.2.3.5.2.2. Market
Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2019 - 2020
10.2.3.5.3.2. Market
Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2019 - 2020
10.2.3.5.4.2. Market
Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2019 - 2020
10.2.3.5.5.2. Market
Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Route of Administration
11. Global Radiopharmaceutical Theragnostic Market Analysis and
Forecasts, 2021 – 2029
11.1. Overview
11.2. Global
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts, By End
Users
11.2.1. Hospitals
and Clinics
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2019 - 2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2019 - 2020
11.2.1.5.1.2. Market
Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2019 - 2020
11.2.1.5.2.2. Market
Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2019 - 2020
11.2.1.5.3.2. Market
Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2019 - 2020
11.2.1.5.4.2. Market
Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2019 - 2020
11.2.1.5.5.2. Market
Forecast, 2021 - 2029
11.2.2. Pharmaceutical
Companies
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2019 - 2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2019 - 2020
11.2.2.5.1.2. Market
Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2019 - 2020
11.2.2.5.2.2. Market
Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2019 - 2020
11.2.2.5.3.2. Market
Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2019 - 2020
11.2.2.5.4.2. Market
Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2019 - 2020
11.2.2.5.5.2. Market
Forecast, 2021 - 2029
11.2.3. Research
Centers
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2019 - 2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2019 - 2020
11.2.3.5.1.2. Market
Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2019 - 2020
11.2.3.5.2.2. Market
Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2019 - 2020
11.2.3.5.3.2. Market
Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2019 - 2020
11.2.3.5.4.2. Market
Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2019 - 2020
11.2.3.5.5.2. Market
Forecast, 2021 - 2029
11.2.4. Others
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2019 - 2020
11.2.4.3. Market Forecast, 2021 - 2029
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market
Estimation, 2019 - 2020
11.2.4.5.1.2. Market
Forecast, 2021 - 2029
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2019 - 2020
11.2.4.5.2.2. Market
Forecast, 2021 - 2029
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market
Estimation, 2019 - 2020
11.2.4.5.3.2. Market
Forecast, 2021 - 2029
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market
Estimation, 2019 - 2020
11.2.4.5.4.2. Market
Forecast, 2021 - 2029
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market
Estimation, 2019 - 2020
11.2.4.5.5.2. Market
Forecast, 2021 - 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By End
Users
12. North America Radiopharmaceutical Theragnostic Market
Analysis and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
12.2. North
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial Phase
12.2.1. Phase I
12.2.2. Phase
II
12.2.3. Phase
III
12.3. North
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Application
12.3.1. Thyroid
cancer
12.3.2. Brain
cancer
12.3.3. Lymphoma
12.3.4. Others
12.4. North
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
12.4.1. Oral
12.4.2. Intravenous
12.4.3. Interstitial
12.5. North
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By End Users
12.5.1. Hospitals
and Clinics
12.5.2. Pharmaceutical
Companies
12.5.3. Research
Centers
12.5.4. Others
12.6. North
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Country
12.6.1. U.S
12.6.1.1. U.S Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
12.6.1.1.1. Phase I
12.6.1.1.2. Phase II
12.6.1.1.3. Phase III
12.6.1.2. U.S Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Application
12.6.1.2.1. Thyroid cancer
12.6.1.2.2. Brain cancer
12.6.1.2.3. Lymphoma
12.6.1.2.4. Others
12.6.1.3. U.S Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
12.6.1.3.1. Oral
12.6.1.3.2. Intravenous
12.6.1.3.3. Interstitial
12.6.1.4. U.S Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By End Users
12.6.1.4.1. Hospitals and Clinics
12.6.1.4.2. Pharmaceutical Companies
12.6.1.4.3. Research Centers
12.6.1.4.4. Others
12.6.2. Canada
12.6.2.1. Canada Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
12.6.2.1.1. Phase I
12.6.2.1.2. Phase II
12.6.2.1.3. Phase III
12.6.2.2. Canada Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
12.6.2.2.1. Thyroid cancer
12.6.2.2.2. Brain cancer
12.6.2.2.3. Lymphoma
12.6.2.2.4. Others
12.6.2.3. Canada Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Route of Administration
12.6.2.3.1. Oral
12.6.2.3.2. Intravenous
12.6.2.3.3. Interstitial
12.6.2.4. Canada Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.2.4.1. Hospitals and Clinics
12.6.2.4.2. Pharmaceutical Companies
12.6.2.4.3. Research Centers
12.6.2.4.4. Others
12.6.3. Mexico
12.6.3.1. Mexico Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
12.6.3.1.1. Phase I
12.6.3.1.2. Phase II
12.6.3.1.3. Phase III
12.6.3.2. Mexico Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
12.6.3.2.1. Thyroid cancer
12.6.3.2.2. Brain cancer
12.6.3.2.3. Lymphoma
12.6.3.2.4. Others
12.6.3.3. Mexico Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Route of Administration
12.6.3.3.1. Oral
12.6.3.3.2. Intravenous
12.6.3.3.3. Interstitial
12.6.3.4. Mexico Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.3.4.1. Hospitals and Clinics
12.6.3.4.2. Pharmaceutical Companies
12.6.3.4.3. Research Centers
12.6.3.4.4. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
12.6.4.1.1. Phase I
12.6.4.1.2. Phase II
12.6.4.1.3. Phase III
12.6.4.2. Rest of North America Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Application
12.6.4.2.1. Thyroid cancer
12.6.4.2.2. Brain cancer
12.6.4.2.3. Lymphoma
12.6.4.2.4. Others
12.6.4.3. Rest of North America Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.4.3.1. Oral
12.6.4.3.2. Intravenous
12.6.4.3.3. Interstitial
12.6.4.4. Rest of North America Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1. Hospitals and Clinics
12.6.4.4.2. Pharmaceutical Companies
12.6.4.4.3. Research Centers
12.6.4.4.4. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Clinical Trial Phase
12.7.3. By
Application
12.7.4. By
Route of Administration
12.7.5. By End
Users
13. Europe Radiopharmaceutical Theragnostic Market Analysis and
Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Europe
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
13.2. Europe
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phase
13.2.1. Phase I
13.2.2. Phase
II
13.2.3. Phase
III
13.3. Europe
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts, By
Application
13.3.1. Thyroid
cancer
13.3.2. Brain
cancer
13.3.3. Lymphoma
13.3.4. Others
13.4. Europe
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
13.4.1. Oral
13.4.2. Intravenous
13.4.3. Interstitial
13.5. Europe
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts, By End
Users
13.5.1. Hospitals
and Clinics
13.5.2. Pharmaceutical
Companies
13.5.3. Research
Centers
13.5.4. Others
13.6. Europe
Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.1. France
13.6.1.1. France Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
13.6.1.1.1. Phase I
13.6.1.1.2. Phase II
13.6.1.1.3. Phase III
13.6.1.2. France Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
13.6.1.2.1. Thyroid cancer
13.6.1.2.2. Brain cancer
13.6.1.2.3. Lymphoma
13.6.1.2.4. Others
13.6.1.3. France Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.6.1.3.1. Oral
13.6.1.3.2. Intravenous
13.6.1.3.3. Interstitial
13.6.1.4. France Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.1.4.1. Hospitals and Clinics
13.6.1.4.2. Pharmaceutical Companies
13.6.1.4.3. Research Centers
13.6.1.4.4. Others
13.6.2. The UK
13.6.2.1. The UK Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
13.6.2.1.1. Phase I
13.6.2.1.2. Phase II
13.6.2.1.3. Phase III
13.6.2.2. The UK Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
13.6.2.2.1. Thyroid cancer
13.6.2.2.2. Brain cancer
13.6.2.2.3. Lymphoma
13.6.2.2.4. Others
13.6.2.3. The UK Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.6.2.3.1. Oral
13.6.2.3.2. Intravenous
13.6.2.3.3. Interstitial
13.6.2.4. The UK Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.2.4.1. Hospitals and Clinics
13.6.2.4.2. Pharmaceutical Companies
13.6.2.4.3. Research Centers
13.6.2.4.4. Others
13.6.3. Spain
13.6.3.1. Spain Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
13.6.3.1.1. Phase I
13.6.3.1.2. Phase II
13.6.3.1.3. Phase III
13.6.3.2. Spain Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.3.2.1. Thyroid cancer
13.6.3.2.2. Brain cancer
13.6.3.2.3. Lymphoma
13.6.3.2.4. Others
13.6.3.3. Spain Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.3.3.1. Oral
13.6.3.3.2. Intravenous
13.6.3.3.3. Interstitial
13.6.3.4. Spain Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By End Users
13.6.3.4.1. Hospitals and Clinics
13.6.3.4.2. Pharmaceutical Companies
13.6.3.4.3. Research Centers
13.6.3.4.4. Others
13.6.4. Germany
13.6.4.1. Germany Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
13.6.4.1.1. Phase I
13.6.4.1.2. Phase II
13.6.4.1.3. Phase III
13.6.4.2. Germany Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
13.6.4.2.1. Thyroid cancer
13.6.4.2.2. Brain cancer
13.6.4.2.3. Lymphoma
13.6.4.2.4. Others
13.6.4.3. Germany Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.6.4.3.1. Oral
13.6.4.3.2. Intravenous
13.6.4.3.3. Interstitial
13.6.4.4. Germany Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.4.4.1. Hospitals and Clinics
13.6.4.4.2. Pharmaceutical Companies
13.6.4.4.3. Research Centers
13.6.4.4.4. Others
13.6.5. Italy
13.6.5.1. Italy Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
13.6.5.1.1. Phase I
13.6.5.1.2. Phase II
13.6.5.1.3. Phase III
13.6.5.2. Italy Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.5.2.1. Thyroid cancer
13.6.5.2.2. Brain cancer
13.6.5.2.3. Lymphoma
13.6.5.2.4. Others
13.6.5.3. Italy Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.5.3.1. Oral
13.6.5.3.2. Intravenous
13.6.5.3.3. Interstitial
13.6.5.4. Italy Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By End Users
13.6.5.4.1. Hospitals and Clinics
13.6.5.4.2. Pharmaceutical Companies
13.6.5.4.3. Research Centers
13.6.5.4.4. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
13.6.6.1.1. Phase I
13.6.6.1.2. Phase II
13.6.6.1.3. Phase III
13.6.6.2. Nordic Countries Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Application
13.6.6.2.1. Thyroid cancer
13.6.6.2.2. Brain cancer
13.6.6.2.3. Lymphoma
13.6.6.2.4. Others
13.6.6.3. Nordic Countries Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.6.3.1. Oral
13.6.6.3.2. Intravenous
13.6.6.3.3. Interstitial
13.6.6.4. Nordic Countries Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1. Hospitals and Clinics
13.6.6.4.2. Pharmaceutical Companies
13.6.6.4.3. Research Centers
13.6.6.4.4. Others
13.6.6.5. Nordic Countries Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
13.6.7.1.1. Phase I
13.6.7.1.2. Phase II
13.6.7.1.3. Phase III
13.6.7.2. Benelux Union Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.7.2.1. Thyroid cancer
13.6.7.2.2. Brain cancer
13.6.7.2.3. Lymphoma
13.6.7.2.4. Others
13.6.7.3. Benelux Union Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.7.3.1. Oral
13.6.7.3.2. Intravenous
13.6.7.3.3. Interstitial
13.6.7.4. Benelux Union Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By End Users
13.6.7.4.1. Hospitals and Clinics
13.6.7.4.2. Pharmaceutical Companies
13.6.7.4.3. Research Centers
13.6.7.4.4. Others
13.6.7.5. Benelux Union Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
13.6.8.1.1. Phase I
13.6.8.1.2. Phase II
13.6.8.1.3. Phase III
13.6.8.2. Rest of Europe Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.8.2.1. Thyroid cancer
13.6.8.2.2. Brain cancer
13.6.8.2.3. Lymphoma
13.6.8.2.4. Others
13.6.8.3. Rest of Europe Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.8.3.1. Oral
13.6.8.3.2. Intravenous
13.6.8.3.3. Interstitial
13.6.8.4. Rest of Europe Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By End Users
13.6.8.4.1. Hospitals and Clinics
13.6.8.4.2. Pharmaceutical Companies
13.6.8.4.3. Research Centers
13.6.8.4.4. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Clinical Trial Phase
13.7.3. By
Application
13.7.4. By
Route of Administration
13.7.5. By End
Users
14. Asia Pacific Radiopharmaceutical Theragnostic Market Analysis
and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia
Pacific Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
14.2. Asia
Pacific Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial Phase
14.2.1. Phase I
14.2.2. Phase
II
14.2.3. Phase
III
14.3. Asia
Pacific Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Application
14.3.1. Thyroid
cancer
14.3.2. Brain
cancer
14.3.3. Lymphoma
14.3.4. Others
14.4. Asia
Pacific Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
14.4.1. Oral
14.4.2. Intravenous
14.4.3. Interstitial
14.5. Asia
Pacific Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By End Users
14.5.1. Hospitals
and Clinics
14.5.2. Pharmaceutical
Companies
14.5.3. Research
Centers
14.5.4. Others
14.6. Asia
Pacific Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Country
14.6.1. China
14.6.1.1. China Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
14.6.1.1.1. Phase I
14.6.1.1.2. Phase II
14.6.1.1.3. Phase III
14.6.1.2. China Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.1.2.1. Thyroid cancer
14.6.1.2.2. Brain cancer
14.6.1.2.3. Lymphoma
14.6.1.2.4. Others
14.6.1.3. China Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.6.1.3.1. Oral
14.6.1.3.2. Intravenous
14.6.1.3.3. Interstitial
14.6.1.4. China Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By End Users
14.6.1.4.1. Hospitals and Clinics
14.6.1.4.2. Pharmaceutical Companies
14.6.1.4.3. Research Centers
14.6.1.4.4. Others
14.6.2. Japan
14.6.2.1. Japan Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
14.6.2.1.1. Phase I
14.6.2.1.2. Phase II
14.6.2.1.3. Phase III
14.6.2.2. Japan Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.2.2.1. Thyroid cancer
14.6.2.2.2. Brain cancer
14.6.2.2.3. Lymphoma
14.6.2.2.4. Others
14.6.2.3. Japan Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.6.2.3.1. Oral
14.6.2.3.2. Intravenous
14.6.2.3.3. Interstitial
14.6.2.4. Japan Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By End Users
14.6.2.4.1. Hospitals and Clinics
14.6.2.4.2. Pharmaceutical Companies
14.6.2.4.3. Research Centers
14.6.2.4.4. Others
14.6.3. India
14.6.3.1. India Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
14.6.3.1.1. Phase I
14.6.3.1.2. Phase II
14.6.3.1.3. Phase III
14.6.3.2. India Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.3.2.1. Thyroid cancer
14.6.3.2.2. Brain cancer
14.6.3.2.3. Lymphoma
14.6.3.2.4. Others
14.6.3.3. India Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.6.3.3.1. Oral
14.6.3.3.2. Intravenous
14.6.3.3.3. Interstitial
14.6.3.4. India Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By End Users
14.6.3.4.1. Hospitals and Clinics
14.6.3.4.2. Pharmaceutical Companies
14.6.3.4.3. Research Centers
14.6.3.4.4. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
14.6.4.1.1. Phase I
14.6.4.1.2. Phase II
14.6.4.1.3. Phase III
14.6.4.2. New Zealand Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
14.6.4.2.1. Thyroid cancer
14.6.4.2.2. Brain cancer
14.6.4.2.3. Lymphoma
14.6.4.2.4. Others
14.6.4.3. New Zealand Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.4.3.1. Oral
14.6.4.3.2. Intravenous
14.6.4.3.3. Interstitial
14.6.4.4. New Zealand Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.4.4.1. Hospitals and Clinics
14.6.4.4.2. Pharmaceutical Companies
14.6.4.4.3. Research Centers
14.6.4.4.4. Others
14.6.5. Australia
14.6.5.1. Australia Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
14.6.5.1.1. Phase I
14.6.5.1.2. Phase II
14.6.5.1.3. Phase III
14.6.5.2. Australia Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
14.6.5.2.1. Thyroid cancer
14.6.5.2.2. Brain cancer
14.6.5.2.3. Lymphoma
14.6.5.2.4. Others
14.6.5.3. Australia Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.6.5.3.1. Oral
14.6.5.3.2. Intravenous
14.6.5.3.3. Interstitial
14.6.5.4. Australia Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.5.4.1. Hospitals and Clinics
14.6.5.4.2. Pharmaceutical Companies
14.6.5.4.3. Research Centers
14.6.5.4.4. Others
14.6.6. South
Korea
14.6.6.1. South Korea Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
14.6.6.1.1. Phase I
14.6.6.1.2. Phase II
14.6.6.1.3. Phase III
14.6.6.2. South Korea Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.6.2.1. Thyroid cancer
14.6.6.2.2. Brain cancer
14.6.6.2.3. Lymphoma
14.6.6.2.4. Others
14.6.6.3. South Korea Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.6.3.1. Oral
14.6.6.3.2. Intravenous
14.6.6.3.3. Interstitial
14.6.6.4. South Korea Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.6.4.1. Hospitals and Clinics
14.6.6.4.2. Pharmaceutical Companies
14.6.6.4.3. Research Centers
14.6.6.4.4. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
14.6.7.1.1. Phase I
14.6.7.1.2. Phase II
14.6.7.1.3. Phase III
14.6.7.2. Southeast Asia Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.7.2.1. Thyroid cancer
14.6.7.2.2. Brain cancer
14.6.7.2.3. Lymphoma
14.6.7.2.4. Others
14.6.7.3. Southeast Asia Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.7.3.1. Oral
14.6.7.3.2. Intravenous
14.6.7.3.3. Interstitial
14.6.7.4. Southeast Asia Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.7.4.1. Hospitals and Clinics
14.6.7.4.2. Pharmaceutical Companies
14.6.7.4.3. Research Centers
14.6.7.4.4. Others
14.6.7.5. Southeast Asia Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.6.8.1.1. Phase I
14.6.8.1.2. Phase II
14.6.8.1.3. Phase III
14.6.8.2. Rest of Asia Pacific Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.8.2.1. Thyroid cancer
14.6.8.2.2. Brain cancer
14.6.8.2.3. Lymphoma
14.6.8.2.4. Others
14.6.8.3. Rest of Asia Pacific Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.8.3.1. Oral
14.6.8.3.2. Intravenous
14.6.8.3.3. Interstitial
14.6.8.4. Rest of Asia Pacific Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1. Hospitals and Clinics
14.6.8.4.2. Pharmaceutical Companies
14.6.8.4.3. Research Centers
14.6.8.4.4. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Clinical Trial Phase
14.7.3. By
Application
14.7.4. By
Route of Administration
14.7.5. By End
Users
15. Middle East and Africa Radiopharmaceutical Theragnostic
Market Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle
East and Africa Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
15.2. Middle
East and Africa Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial Phase
15.2.1. Phase I
15.2.2. Phase
II
15.2.3. Phase
III
15.3. Middle
East and Africa Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and
Forecasts, By Application
15.3.1. Thyroid
cancer
15.3.2. Brain
cancer
15.3.3. Lymphoma
15.3.4. Others
15.4. Middle
East and Africa Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.4.1. Oral
15.4.2. Intravenous
15.4.3. Interstitial
15.5. Middle
East and Africa Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and
Forecasts, By End Users
15.5.1. Hospitals
and Clinics
15.5.2. Pharmaceutical
Companies
15.5.3. Research
Centers
15.5.4. Others
15.6. Middle
East and Africa Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and
Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
15.6.1.1.1. Phase I
15.6.1.1.2. Phase II
15.6.1.1.3. Phase III
15.6.1.2. Saudi Arabia Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.1.2.1. Thyroid cancer
15.6.1.2.2. Brain cancer
15.6.1.2.3. Lymphoma
15.6.1.2.4. Others
15.6.1.3. Saudi Arabia Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.6.1.3.1. Oral
15.6.1.3.2. Intravenous
15.6.1.3.3. Interstitial
15.6.1.4. Saudi Arabia Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By End Users
15.6.1.4.1. Hospitals and Clinics
15.6.1.4.2. Pharmaceutical Companies
15.6.1.4.3. Research Centers
15.6.1.4.4. Others
15.6.2. UAE
15.6.2.1. UAE Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
15.6.2.1.1. Phase I
15.6.2.1.2. Phase II
15.6.2.1.3. Phase III
15.6.2.2. UAE Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.2.2.1. Thyroid cancer
15.6.2.2.2. Brain cancer
15.6.2.2.3. Lymphoma
15.6.2.2.4. Others
15.6.2.3. UAE Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.6.2.3.1. Oral
15.6.2.3.2. Intravenous
15.6.2.3.3. Interstitial
15.6.2.4. UAE Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.2.4.1. Hospitals and Clinics
15.6.2.4.2. Pharmaceutical Companies
15.6.2.4.3. Research Centers
15.6.2.4.4. Others
15.6.3. Egypt
15.6.3.1. Egypt Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
15.6.3.1.1. Phase I
15.6.3.1.2. Phase II
15.6.3.1.3. Phase III
15.6.3.2. Egypt Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.3.2.1. Thyroid cancer
15.6.3.2.2. Brain cancer
15.6.3.2.3. Lymphoma
15.6.3.2.4. Others
15.6.3.3. Egypt Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.6.3.3.1. Oral
15.6.3.3.2. Intravenous
15.6.3.3.3. Interstitial
15.6.3.4. Egypt Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.3.4.1. Hospitals and Clinics
15.6.3.4.2. Pharmaceutical Companies
15.6.3.4.3. Research Centers
15.6.3.4.4. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
15.6.4.1.1. Phase I
15.6.4.1.2. Phase II
15.6.4.1.3. Phase III
15.6.4.2. Kuwait Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
15.6.4.2.1. Thyroid cancer
15.6.4.2.2. Brain cancer
15.6.4.2.3. Lymphoma
15.6.4.2.4. Others
15.6.4.3. Kuwait Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.6.4.3.1. Oral
15.6.4.3.2. Intravenous
15.6.4.3.3. Interstitial
15.6.4.4. Kuwait Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By End Users
15.6.4.4.1. Hospitals and Clinics
15.6.4.4.2. Pharmaceutical Companies
15.6.4.4.3. Research Centers
15.6.4.4.4. Others
15.6.5. South
Africa
15.6.5.1. South Africa Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
15.6.5.1.1. Phase I
15.6.5.1.2. Phase II
15.6.5.1.3. Phase III
15.6.5.2. South Africa Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.5.2.1. Thyroid cancer
15.6.5.2.2. Brain cancer
15.6.5.2.3. Lymphoma
15.6.5.2.4. Others
15.6.5.3. South Africa Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.6.5.3.1. Oral
15.6.5.3.2. Intravenous
15.6.5.3.3. Interstitial
15.6.5.4. South Africa Radiopharmaceutical Theragnostic Market Revenue
(US$ Mn) and Forecasts, By End Users
15.6.5.4.1. Hospitals and Clinics
15.6.5.4.2. Pharmaceutical Companies
15.6.5.4.3. Research Centers
15.6.5.4.4. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Radiopharmaceutical
Theragnostic Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.6.6.1.1. Phase I
15.6.6.1.2. Phase II
15.6.6.1.3. Phase III
15.6.6.2. Rest of Middle East & Africa Radiopharmaceutical
Theragnostic Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.2.1. Thyroid cancer
15.6.6.2.2. Brain cancer
15.6.6.2.3. Lymphoma
15.6.6.2.4. Others
15.6.6.3. Rest of Middle East & Africa Radiopharmaceutical
Theragnostic Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.6.3.1. Oral
15.6.6.3.2. Intravenous
15.6.6.3.3. Interstitial
15.6.6.4. Rest of Middle East & Africa Radiopharmaceutical
Theragnostic Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1. Hospitals and Clinics
15.6.6.4.2. Pharmaceutical Companies
15.6.6.4.3. Research Centers
15.6.6.4.4. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Clinical Trial Phase
15.7.3. By
Application
15.7.4. By
Route of Administration
15.7.5. By End
Users
16. Latin America Radiopharmaceutical Theragnostic Market Analysis
and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn)
16.2. Latin
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial Phase
16.2.1. Phase I
16.2.2. Phase
II
16.2.3. Phase
III
16.3. Latin
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Application
16.3.1. Thyroid
cancer
16.3.2. Brain
cancer
16.3.3. Lymphoma
16.3.4. Others
16.4. Latin
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
16.4.1. Oral
16.4.2. Intravenous
16.4.3. Interstitial
16.5. Latin
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By End Users
16.5.1. Hospitals
and Clinics
16.5.2. Pharmaceutical
Companies
16.5.3. Research
Centers
16.5.4. Others
16.6. Latin
America Radiopharmaceutical Theragnostic Market Revenue (US$ Mn) and Forecasts,
By Country
16.6.1. Brazil
16.6.1.1. Brazil Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
16.6.1.1.1. Phase I
16.6.1.1.2. Phase II
16.6.1.1.3. Phase III
16.6.1.2. Brazil Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
16.6.1.2.1. Thyroid cancer
16.6.1.2.2. Brain cancer
16.6.1.2.3. Lymphoma
16.6.1.2.4. Others
16.6.1.3. Brazil Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Route of Administration
16.6.1.3.1. Oral
16.6.1.3.2. Intravenous
16.6.1.3.3. Interstitial
16.6.1.4. Brazil Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By End Users
16.6.1.4.1. Hospitals and Clinics
16.6.1.4.2. Pharmaceutical Companies
16.6.1.4.3. Research Centers
16.6.1.4.4. Others
16.6.2. Argentina
16.6.2.1. Argentina Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
16.6.2.1.1. Phase I
16.6.2.1.2. Phase II
16.6.2.1.3. Phase III
16.6.2.2. Argentina Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Application
16.6.2.2.1. Thyroid cancer
16.6.2.2.2. Brain cancer
16.6.2.2.3. Lymphoma
16.6.2.2.4. Others
16.6.2.3. Argentina Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By Route of Administration
16.6.2.3.1. Oral
16.6.2.3.2. Intravenous
16.6.2.3.3. Interstitial
16.6.2.4. Argentina Radiopharmaceutical Theragnostic Market Revenue (US$
Mn) and Forecasts, By End Users
16.6.2.4.1. Hospitals and Clinics
16.6.2.4.2. Pharmaceutical Companies
16.6.2.4.3. Research Centers
16.6.2.4.4. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
16.6.3.1.1. Phase I
16.6.3.1.2. Phase II
16.6.3.1.3. Phase III
16.6.3.2. Rest of Latin America Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Application
16.6.3.2.1. Thyroid cancer
16.6.3.2.2. Brain cancer
16.6.3.2.3. Lymphoma
16.6.3.2.4. Others
16.6.3.3. Rest of Latin America Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.6.3.3.1. Oral
16.6.3.3.2. Intravenous
16.6.3.3.3. Interstitial
16.6.3.4. Rest of Latin America Radiopharmaceutical Theragnostic Market
Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.4.1. Hospitals and Clinics
16.6.3.4.2. Pharmaceutical Companies
16.6.3.4.3. Research Centers
16.6.3.4.4. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Clinical Trial Phase
16.7.3. By
Application
16.7.4. By
Route of Administration
16.7.5. By End
Users
17. Competitive Benchmarking
17.1. Brand
Benchmarking
17.2. Market
Share Analysis, 2020
17.3. Global
Presence and Growth Strategies
17.3.1. Mergers
and Acquisitions
17.3.2. Product
Launches
17.3.3. Investments
Trends
17.3.4. R&D
Initiatives
18. Player Profiles
18.1. Advanced
Accelerator Applications, A Novartis Company
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business Strategies
18.2. Chimeric Therapeutics Limited
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business Strategies
18.3. Fusion Pharma
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business Strategies
18.4. Lantheus Medical Imaging, Inc.
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business Strategies
18.5. NanoMab
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business Strategies
18.6. NuView Life Sciences.
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business Strategies
18.7. PentixaPharm GmbH,
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business Strategies
18.8. Precirix
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business Strategies
18.9. RadioMedix
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business Strategies
18.10. RayzeBio
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business Strategies
18.11. Telix Pharmaceuticals Limited
18.11.1.
Company Details
18.11.2.
Company Overview
18.11.3.
Product Offerings
18.11.4.
Key Developments
18.11.5.
Financial Analysis
18.11.6.
SWOT Analysis
18.11.7. Business Strategies
18.12. Theragnostics Ltd
18.12.1.
Company Details
18.12.2.
Company Overview
18.12.3.
Product Offerings
18.12.4.
Key Developments
18.12.5.
Financial Analysis
18.12.6.
SWOT Analysis
18.12.7. Business Strategies
18.13. Vect-Horus
18.13.1.
Company Details
18.13.2.
Company Overview
18.13.3.
Product Offerings
18.13.4.
Key Developments
18.13.5.
Financial Analysis
18.13.6.
SWOT Analysis
18.13.7. Business Strategies
18.14. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.